CN105228614A - 用于治疗神经退化疾病和其它疾病的组合治疗剂和方法 - Google Patents
用于治疗神经退化疾病和其它疾病的组合治疗剂和方法 Download PDFInfo
- Publication number
- CN105228614A CN105228614A CN201380070968.5A CN201380070968A CN105228614A CN 105228614 A CN105228614 A CN 105228614A CN 201380070968 A CN201380070968 A CN 201380070968A CN 105228614 A CN105228614 A CN 105228614A
- Authority
- CN
- China
- Prior art keywords
- bryostatin
- retinoid
- article
- effective amount
- manufacture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Botany (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Ophthalmology & Optometry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261730761P | 2012-11-28 | 2012-11-28 | |
| US61/730761 | 2012-11-28 | ||
| PCT/US2013/072076 WO2014085494A1 (en) | 2012-11-28 | 2013-11-26 | Combination therapeutics and methods for the treatment of neurodegenerative and other diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105228614A true CN105228614A (zh) | 2016-01-06 |
Family
ID=50828429
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380070968.5A Pending CN105228614A (zh) | 2012-11-28 | 2013-11-26 | 用于治疗神经退化疾病和其它疾病的组合治疗剂和方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10828276B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2925314B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6579956B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN105228614A (cg-RX-API-DMAC7.html) |
| HK (1) | HK1218882A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014085494A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9994585B2 (en) | 2007-12-31 | 2018-06-12 | Aphios Corporation | Transplantation therapies |
| US9034347B2 (en) | 2011-12-19 | 2015-05-19 | Arphios Corporation | Drug delivery system and method for the treatment of neuro-degenerative disease |
| JP6579956B2 (ja) | 2012-11-28 | 2019-09-25 | アフィオス コーポレーション | 神経変性疾患および他の疾患の治療のための併用治療薬および方法 |
| WO2026024784A1 (en) * | 2024-07-22 | 2026-01-29 | Mastery Biotech Co., Ltd. | Composition and method for preventing or treating neurodegenerative diseases |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1678304A (zh) * | 2002-07-02 | 2005-10-05 | 布朗歇特洛克菲勒神经科学研究所 | 使用苔藓抑制素类化合物活化PKC作为增强sAPPα分泌和改善认知的方法 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4560774A (en) * | 1982-11-17 | 1985-12-24 | Arizona State University | Macrocyclic lactones |
| US4611066A (en) * | 1984-08-10 | 1986-09-09 | Arizona State University | Bryostatins 4 to 8 |
| US5440055A (en) | 1993-03-12 | 1995-08-08 | Aphios Corporation | Method and apparatus for extracting taxol from source materials |
| US5854064A (en) | 1996-07-31 | 1998-12-29 | Aphios Corporation | Methods for fractionation of biologically-derived materials |
| GB9325395D0 (en) | 1993-12-11 | 1994-02-16 | Ciba Geigy Ag | Compositions |
| IE75744B1 (en) | 1995-04-03 | 1997-09-24 | Elan Corp Plc | Controlled release biodegradable micro- and nanospheres containing cyclosporin |
| EP0888458A4 (en) | 1996-02-20 | 2004-05-06 | Sloan Kettering Institutefor C | COMBINATION OF PKC INHIBITORS AND THERAPEUTIC AGENTS FOR TREATING CANCER |
| GB9620390D0 (en) | 1996-09-30 | 1996-11-13 | Eisai London Res Lab Ltd | Substances and their uses |
| US6221153B1 (en) | 1998-06-09 | 2001-04-24 | Trevor Percival Castor | Method for producing large crystals of complex molecules |
| US6228843B1 (en) | 1999-04-23 | 2001-05-08 | University Technology Corporation | Method of using PKC inhibiting compounds to treat vascular disease |
| CA2393026A1 (en) | 1999-11-30 | 2001-06-07 | Paul A. Wender | Bryostatin analogues, synthetic methods and uses |
| WO2002028387A1 (en) * | 2000-10-03 | 2002-04-11 | Oncopharmaceutical, Inc. | Inhibitors of angiogenesis and tumor growth for local and systemic administration |
| US20080004332A1 (en) | 2002-03-07 | 2008-01-03 | Alkon Daniel L | Methods for alzheimer's disease treatment and cognitive enhancement |
| US6825229B2 (en) | 2002-03-07 | 2004-11-30 | Blanchette Rockefeller Neurosciences Institute | Methods for Alzheimer's Disease treatment and cognitive enhancement |
| WO2003086369A2 (en) * | 2002-04-05 | 2003-10-23 | Valorisation-Recherche, Societe En Commandite | Stealthy polymeric biodegradable nanospheres and uses thereof |
| JP4890759B2 (ja) | 2002-07-02 | 2012-03-07 | ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート | sAPPα分泌を増強させる及びブリオスタチン型化合物を用いて認知を改善させるための手段としてのPKC活性化 |
| US8088605B2 (en) * | 2002-12-04 | 2012-01-03 | Technologies Biolactics Inc. | Exopolysaccharides delivery system for active molecules |
| AU2005240078A1 (en) | 2004-04-30 | 2005-11-17 | Allergan, Inc. | Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing |
| US7871358B2 (en) * | 2005-10-14 | 2011-01-18 | Gary Graham | Height adjustable shuttle treatment table/exercise device method and apparatus |
| WO2007114881A1 (en) | 2006-01-24 | 2007-10-11 | Nexbio, Inc. | Technology for preparation of macromolecular microspheres |
| CN101848726A (zh) | 2007-02-09 | 2010-09-29 | 布朗歇特洛克菲勒神经科学研究所 | 苔藓抑素、苔藓抑素类似物和其它相关物质对头部创伤引起的记忆缺陷和脑损伤的疗效 |
| US8071119B2 (en) * | 2007-05-14 | 2011-12-06 | Sustained Nano Systems Llc | Controlled release implantable dispensing device and method |
| US8497385B2 (en) * | 2007-08-31 | 2013-07-30 | The Board Of Trustees Of The Leland Stanford Junior University | Bryostatin analogues, synthetic methods and uses |
| US9994585B2 (en) | 2007-12-31 | 2018-06-12 | Aphios Corporation | Transplantation therapies |
| US20100168219A1 (en) | 2008-12-31 | 2010-07-01 | Jonathan Steven Alexander | Chronic inflammation and transplantation |
| US20120309818A1 (en) | 2007-12-31 | 2012-12-06 | Jonathan Steven Alexander | Chronic inflammation and transplantation |
| WO2009129361A2 (en) | 2008-04-16 | 2009-10-22 | University Of Utah Research Foundation | Macrocyclic compounds and methods of making and using thereof |
| WO2009132050A2 (en) | 2008-04-21 | 2009-10-29 | Otonomy, Inc. | Auris formulations for treating otic diseases and conditions |
| US20110129450A1 (en) * | 2008-08-01 | 2011-06-02 | Orly Lazarov | Method of promoting neurogenesis by modulating secretase activities |
| US20100166806A1 (en) * | 2008-12-29 | 2010-07-01 | Aphios Corporation | Combination therapy comprising the use of protein kinase C modulators and Histone Deacetylase inhibitors for treating HIV-1 latency |
| CN102459180B (zh) * | 2009-06-09 | 2014-05-14 | 江苏迈度药物研发有限公司 | 作为激酶抑制剂的脲衍生物 |
| WO2013071282A1 (en) * | 2011-11-13 | 2013-05-16 | Blanchette Rockefeller Neurosciences Institute | Pkc activators and combinations thereof |
| US9034347B2 (en) | 2011-12-19 | 2015-05-19 | Arphios Corporation | Drug delivery system and method for the treatment of neuro-degenerative disease |
| CN105008342B (zh) | 2012-11-27 | 2018-10-19 | 阿菲欧斯公司 | 苔藓素组合物、其制备方法和用途 |
| JP6579956B2 (ja) | 2012-11-28 | 2019-09-25 | アフィオス コーポレーション | 神経変性疾患および他の疾患の治療のための併用治療薬および方法 |
-
2013
- 2013-11-26 JP JP2015545197A patent/JP6579956B2/ja not_active Expired - Fee Related
- 2013-11-26 US US14/646,817 patent/US10828276B2/en active Active
- 2013-11-26 EP EP13858873.6A patent/EP2925314B1/en active Active
- 2013-11-26 CN CN201380070968.5A patent/CN105228614A/zh active Pending
- 2013-11-26 HK HK16106972.1A patent/HK1218882A1/zh unknown
- 2013-11-26 WO PCT/US2013/072076 patent/WO2014085494A1/en not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1678304A (zh) * | 2002-07-02 | 2005-10-05 | 布朗歇特洛克菲勒神经科学研究所 | 使用苔藓抑制素类化合物活化PKC作为增强sAPPα分泌和改善认知的方法 |
Non-Patent Citations (4)
| Title |
|---|
| 《FEBS JOURNAL》 * |
| A. M. JETTEN等: "Effects of Bryostatins and Retinoic Acid on Phorbol Ester- and Diacylglycero-induced Squamous Differentiation in Human Tracheobronchial Epithelial Cell", 《CANCER RESEARCH》 * |
| HYUN-PIL LEE等: "All-trans retinoic acid as a novel therapeutic strategy for Alzheimer’s disease", 《EXPERT REV.NEUROTHER》 * |
| R.STONE等: "THE COMBINATION OF ALL-TRANS RETINOIC ACID (ATRA) AND BRYOSTATIN 1 (BRYO) INDUCES MONOCYTIC DIFFERENTATION (MD) IN HUMAN MYELOID LEUKEMIA", 《LEUKEMIA RESEARCH》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014085494A1 (en) | 2014-06-05 |
| JP2016501225A (ja) | 2016-01-18 |
| WO2014085494A8 (en) | 2015-04-23 |
| EP2925314B1 (en) | 2020-04-01 |
| US10828276B2 (en) | 2020-11-10 |
| EP2925314A1 (en) | 2015-10-07 |
| US20150297555A1 (en) | 2015-10-22 |
| JP6579956B2 (ja) | 2019-09-25 |
| EP2925314A4 (en) | 2016-06-01 |
| HK1218882A1 (zh) | 2017-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10485766B2 (en) | Drug delivery system and method for the treatment of neuro-degenerative disease | |
| US10799517B2 (en) | Oral composition of celecoxib for treatment of pain | |
| CN114796110A (zh) | 一种不含乙醇的难溶性药物浓缩液以及由其制备的胶束溶液 | |
| WO2017045034A1 (en) | Ubiquinone and ubiquinol compositions, and methods relating thereto | |
| US10828276B2 (en) | Combination therapeutics and methods for the treatment of neurodegenerative and other diseases | |
| US20210030678A1 (en) | Cannabinoid and cbd liposome formulations and uses thereof | |
| Yang et al. | Pharmacological management of cancer pain: Advances in treatment strategies and drug delivery systems | |
| US20220142934A1 (en) | Combination therapeutics and methods for the treatment of neurodegenerative and other diseases | |
| CN1698620B (zh) | 一种可过滤除菌的葫芦素乳剂及制备方法 | |
| US20200397701A1 (en) | Drug delivery system and method for the treatment of neuro-degenerative disease | |
| CN115400078A (zh) | 一种塞来昔布乳状注射液及其制备方法 | |
| EP3883547B1 (en) | Preparation and use of cannabis nano-formulation | |
| CN111407725B (zh) | 一种拉莫三嗪乳剂及其制备方法 | |
| CN110115766B (zh) | 一种含有氟比洛芬酯的复方制剂及其制备方法 | |
| CN109200018A (zh) | 含有奈妥吡坦的微乳制剂 | |
| CN100560058C (zh) | 一种口服、快速起效的镇痛药物 | |
| CN102525913A (zh) | 丁酸氢化可的松和含辅料的水构成的治疗皮肤病的分离式水混悬剂药物 | |
| TR2024018865A2 (tr) | KLORFENİRAMİN/PARASETAMOL ve KLORFENİRAMİN/PARASETAMOL KUANTUM NOKTALARINI İÇEREN TRANSDERMAL TERAPÖTİK SİSTEMLERİN HAZIRLANMASI | |
| CN102475708A (zh) | 丙酸氟替卡松和含辅料的水构成的治疗皮肤病的分离式水混悬剂药物 | |
| CN102552286A (zh) | 糠酸莫米松和含辅料的水构成的治疗皮肤病的分离式水混悬剂药物 | |
| CN113827562A (zh) | 用于口服和胃肠外给药的稳定的氯吡格雷游离碱药物组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1218882 Country of ref document: HK |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160106 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1218882 Country of ref document: HK |